Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

TIRZEPATIDE TREATMENT AND ACHIEVING WEIGHT REDUCTION >5%, SBP REDUCTION >5 MMHG AND NON-HDL CHOLESTEROL REDUCTION >10%: A POST-HOC ANALYSIS FROM THE SURMOUNT-1 3-YEAR TRIAL

Sattar Naveed Glasgow (Uk) – School Of Cardiovascular And Metabolic Health, University Of Glasgow | Le Roux Carel Coleraine (Uk) – Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland And Diabetes Research Centre, Ulster University | Mamas Mamas A. Staffordshire (Uk) – School Of Medicine, Keele University | Wang Hui Indianapolis (Indiana) – Eli Lilly And Company | Mast Casey J. Indianapolis (Indiana) – Eli Lilly And Company | Dimitriadis Georgios K. Indianapolis (Indiana) – Eli Lilly And Company | Lee Clare J. Indianapolis (Indiana) – Eli Lilly And Company | Plat Arian Indianapolis (Indiana) – Eli Lilly And Company

Introduction: This post-hoc analysis evaluated the proportion of participants with obesity and prediabetes who met the combined goal of weight reduction >5%, systolic blood pressure (SBP) reduction >5 mmHg and non-HDL cholesterol reduction >10% from baseline to Week 176 in SURMOUNT-1 3-year trial. Methods: Post-hoc analyses included participants with obesity and prediabetes who completed treatment with tirzepatide (n=454) or placebo (n=114) at Week 176 and had measures for weight, SBP and lipids. Shifts in HbA1c (<5.7%; ≥5.7%), body mass index (BMI) (≤27;>27 kg/m 2 ) and waist:height ratio (WHtR) categories (<0.53; ≥0. 53) from baseline to Week 176 were calculated for those who met the combined clinical goals. Results: 145 (25.5%) participants met the combined goal at Week 176. Significantly more tirzepatide-treated participants (n=139, 30.6%) met the combined goal vs. placebo participants (n=6, 5.3%) (p<0.0001). 94.2% (n=131) of tirzepatide participants who met the combined goal also had an HbA1c <5.7%, while 41.0% (n=57) had a BMI ≤27 kg/m 2 and 28.8% (n=40) had a WHtR <0.53. Conclusion: In this post-hoc analysis, participants treated with tirzepatide were significantly more likely to achieve a combined clinical goal of weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%. The majority of tirzepatide participants meeting the combined goal also achieved normoglycemia. More than 1/3 participants met the BMI goal, and 1/4 participants met the WHtR goal suggesting a reduction in central adiposity.